OYST
NASDAQOyster Point Pharma Inc.
Latest news
25 items- NEWSHealth Care Becomes Most Overweighted Sector As Hedge Funds Crowd Into Magnificent 7Six out of the 10 largest holdings in over 700 aggregated hedge fund portfolios are increasingly concentrated towards the ‘Magnificent Seven' stocks, with Tesla being the sole exception, according to the latest report by Goldman Sachs. What Happened: Insights from Goldman Sachs’ Hedge Fund Trend Monitor, an analysis led by Ben Snider, show an overzealous preference for just several mega-caps. This enthusiasm does not mirror their market weight. The Magnificent Seven accounts for a record 13% of the aggregate hedge fund long portfolios. Yet, it remains significantly underweighted compared to a 26% collective stake in the Russell 3000 — underscoring a cautious approach towards mega-cap
- 13D/GSEC Form SC 13G/A filed by Oyster Point Pharma Inc. (Amendment)SC 13G/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
- 13D/GSEC Form SC 13G/A filed by Oyster Point Pharma Inc. (Amendment)SC 13G/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
- SECSEC Form 15-12G filed by Oyster Point Pharma Inc.15-12G - Oyster Point Pharma, Inc. (0001720725) (Filer)
- SECOyster Point Pharma Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits (Amendment)8-K/A - Oyster Point Pharma, Inc. (0001720725) (Filer)
- 13D/GSEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)SC 13D/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
- 13D/GSEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)SC 13D/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
- SECSEC Form EFFECT filed by Oyster Point Pharma Inc.EFFECT - Oyster Point Pharma, Inc. (0001720725) (Filer)
- 13D/GSEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)SC 13D/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
- INSIDERSEC Form 4 filed by Invopps Gp Iv, L.L.C.4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
- INSIDERSEC Form 4 filed by Versant Venture Capital Vi, L.P.4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
- INSIDERSEC Form 4: Behbahani Ali returned 13,639 shares to the company, closing all direct ownership in the company (for tax liability)4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
- INSIDERSEC Form 4 filed by New Enterprise Associates 14, L.P.4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
- INSIDERSEC Form 4: Weisner Aimee S returned 36,764 shares to the company, closing all direct ownership in the company (for tax liability)4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
- INSIDERSEC Form 4: Tsai Benjamin returned 3,573 shares to the company, closing all direct ownership in the company (withholding obligation)4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
- INSIDERSEC Form 4: Santel Donald J returned 8,198 shares to the company, closing all direct ownership in the company to cover withholding tax4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
- INSIDERSEC Form 4: Ozawa Clare returned 14,637 shares to the company, closing all direct ownership in the company (withholding tax)4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
- INSIDERSEC Form 4: Nau Jeffrey covered exercise/tax liability with 2,607 shares and returned 48,975 shares to the company, closing all direct ownership in the company to satisfy withholding tax4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
- INSIDERSEC Form 4: Murray Mark Anthony returned 122,086 shares to the company, closing all direct ownership in the company to satisfy withholding tax4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
- INSIDERSEC Form 4: Lochner Daniel covered exercise/tax liability with 938 shares and returned 20,236 shares to the company, closing all direct ownership in the company (tax liability)4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
- INSIDERSEC Form 4: Eliades George Christopher returned 28,624 shares to the company, closing all direct ownership in the company (tax liability)4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
- INSIDERSEC Form 4: Atieh Michael G returned 8,671 shares to the company, closing all direct ownership in the company (withholding obligation)4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
- SECSEC Form 25-NSE filed by Oyster Point Pharma Inc.25-NSE - Oyster Point Pharma, Inc. (0001720725) (Subject)
- SECSEC Form S-8 POS filed by Oyster Point Pharma Inc.S-8 POS - Oyster Point Pharma, Inc. (0001720725) (Filer)
- SECSEC Form S-8 POS filed by Oyster Point Pharma Inc.S-8 POS - Oyster Point Pharma, Inc. (0001720725) (Filer)
OYST FAQ
7 questionsWhat does Oyster Point Pharma Inc. do?
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that has completed Phase III clinical trial for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratopathy. Oyster Point Pharma, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.Where does OYST stock trade?
Oyster Point Pharma Inc. (OYST) is listed on NASDAQ.What sector and industry is OYST in?
Oyster Point Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Oyster Point Pharma Inc. go public?
Oyster Point Pharma Inc. (OYST) completed its IPO in 2019.What are analysts saying about OYST?
Oyster Point Pharma Inc. has had 3 recent analyst actions on file. The most recent action was from Chardan Capital Markets: Buy with a $2200.00 price target on 2022-08-11. Recent price targets range from $2000.00 to $2300.00.What companies are similar to OYST?
Notable peers in the same industry include PNT (POINT Biopharma Global Inc.), AVIR (Atea Pharmaceuticals Inc.), HOOK (HOOKIPA Pharma Inc.). Compare OYST side-by-side with any of them on Quantisnow.How can I track OYST on Quantisnow?
Quantisnow aggregates Oyster Point Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OYST to receive live email and push alerts on every new disclosure.